Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Endometrial Ca Risk with Postmenopausal Bleeding

JAMA Intern Med; ePub 2018 Aug 6; Clarke, et al

Early detection strategies focused on women with postmenopausal bleeding (PMB) have the potential to capture 90% of endometrial cancers; however, most women with PMB will not be diagnosed with endometrial cancer. This according to a systematic review and meta-analysis of 40,790 women. Observational studies reporting the prevalence of PMB in women with endometrial cancer and the risk of endometrial cancer in women with PMB in unselected populations were selected. Among the findings:

  • The pooled prevalence of PMB among women with endometrial cancer was 91%.
  • The pooled risk of endometrial cancer among women with PMB was 9%, with estimates varying by use of hormone therapy and geographic region.
  • Researchers suggested that these results can aid in the assessment of the potential clinical value of new early detection markers and clinical management strategies for endometrial cancer.

Citation:

Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of endometrial cancer risk with postmenopausal bleeding in women. A systematic review and meta-analysis. [Published online ahead of print August 6, 2018]. JAMA Intern Med. doi:10.1001/jamainternmed.2018.2820.